Clinical trials
Phase 3 Hypoglycemia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Zealand Pharma | 5 |
| Xeris Pharmaceuticals | 3 |
| Baylor College of Medicine | 2 |
| Eli Lilly and Company | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Rezolute | 2 |
| Albert Einstein Healthcare Network | 1 |
| Amylyx Pharmaceuticals Inc. | 1 |
| Boston Medical Center | 1 |
| Florida Atlantic University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypoglycemia | 26 |
| Diabetes Mellitus, Type 1 | 14 |
| Diabetes Mellitus | 7 |
| Hyperglycemia | 7 |
| Diabetes Mellitus, Type 2 | 2 |
| Hyperinsulinism | 2 |
| Adenoma, Islet Cell | 1 |
| Autoimmune Diseases | 1 |
| Congenital Hyperinsulinism | 1 |
| Diabetes Complications | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.